Skip to main navigation Skip to search Skip to main content

Interaction of endocrine therapy for breast cancer with APOE4 status on cognition over 5-year follow-up

  • Kathleen Van Dyk
  • , Wanting Zhai
  • , Tim A. Ahles
  • , James C. Root
  • , Jaeil Ahn
  • , Ashley L. Artese
  • , Traci N. Bethea
  • , Harvey J. Cohen
  • , Martine Extermann
  • , Deena Graham
  • , Claudine Isaacs
  • , Heather S.L. Jim
  • , Brenna C. McDonald
  • , Zev M. Nakamura
  • , Sunita K. Patel
  • , Kelly E. Rentscher
  • , Andrew J. Saykin
  • , Brent J. Small
  • , Danielle B. Tometich
  • , Xingtao Zhou
  • Judith E. Carroll, Jeanne S. Mandelblatt
  • University of California at Los Angeles
  • City of Hope National Med Center
  • Georgetown University
  • Memorial Sloan-Kettering Cancer Center
  • Florida Atlantic University
  • Duke University
  • University of South Florida
  • Moffitt Cancer Center
  • Indiana University Bloomington
  • University of North Carolina at Chapel Hill
  • Medical College of Wisconsin

Research output: Contribution to journal › Article › peer-review

Abstract

Cognitive effects of breast cancer antiestrogen endocrine therapy are a salient concern for survivors, given the growing evidence that estrogen plays a role in late-life dementia risk. The APOE4 genotype has been linked with risk for cognitive difficulties, studied mainly in younger cancer survivors. We found that women aged 60+ with nonmetastatic breast cancer enrolled in the prospective Thinking and Living with Cancer study who underwent endocrine therapy had lower subjective (P = .06) and objective (P = .08) cognitive function than frequency-matched controls across time. At 5 years, however, women with breast cancer exposed to endocrine therapy and APOE4 carriers in particular exhibited lower learning and memory scores than other groups (P < .05). Our results suggest endocrine therapy may have long-term effects on cognitive function in women with breast cancer, particularly APOE4 carriers. Further characterization of genetic risk for long-term cognitive decline will be useful to inform survivorship care of older women.

Original languageEnglish
JournalJNCI Cancer Spectrum
Volume10
Issue number2
DOIs
StatePublished - Apr 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Interaction of endocrine therapy for breast cancer with APOE4 status on cognition over 5-year follow-up'. Together they form a unique fingerprint.

Cite this